Amazon Web Services on Tuesday introduced Amazon Bio Discovery, a new AI-driven application designed to help scientists design and test drug candidates more efficiently by combining machine learning models with lab-based experimentation.
The platform gives researchers access to a catalog of biological foundation models trained on large-scale biological data. These models can generate and assess potential drug molecules, particularly in the early stages of antibody development. Through a built-in AI agent, scientists can interact using natural language to choose models, refine inputs, and evaluate results without needing specialized coding skills.
Amazon positions the tool as a way to reduce friction in adopting AI for drug discovery. Researchers often face challenges selecting from dozens of models, managing infrastructure, and coordinating with lab partners. The new system brings those steps into a single workflow, pairing model selection with experiment design and execution.
A key component is the integration with external laboratory partners. Once promising candidates are identified, scientists can send them directly for synthesis and testing. Results are then fed back into the system, allowing researchers to iterate more quickly. This creates a continuous feedback loop between computational design and physical validation.
The application also allows users to train models on their own experimental data. By incorporating prior lab results, researchers can generate more tailored predictions without building custom machine learning pipelines. According to AWS, these models remain private to each organization.
“AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise,” said Rajiv Chopra, vice president of AWS Healthcare AI and Life Sciences. “These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment.”
Amazon said the platform builds on infrastructure already used widely in the pharmaceutical industry, noting that most leading drugmakers rely on AWS for research workloads. Early adopters include organizations such as Bayer, the Broad Institute, Fred Hutch Cancer Center, and Voyager Therapeutics.
In one example, researchers at Memorial Sloan Kettering Cancer Center used the system to design nearly 300,000 antibody candidates and narrowed them down for testing in a matter of weeks, a process that traditionally can take much longer.
Amazon Bio Discovery is aimed at pharmaceutical, biotech, and academic researchers looking to streamline early-stage drug development by combining AI model access, experiment design, and lab testing into a unified environment.
See more here:
This analysis is based on reporting from Amazon News.
Image courtesy of Amazon.
This article was generated with AI assistance and reviewed for accuracy and quality.
About this article: This article was generated with AI assistance and reviewed by our editorial team to ensure it follows our editorial standards for accuracy and independence. We maintain strict fact-checking protocols and cite all sources.
Word count: 419Reading time: 0 minutes
Explore More AI Resources
Continue with high-value guides related to this topic.
